Genentech to exercise Fovista rights under Novartis agreement
Roche’s option stems from a pre-existing deal with Novartis. Ophthotech’s agreement with Novartis, which was signed in May last year, remains in effect. Ophthotech retains exclusive rights to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.